Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.

Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

1 st

first to design and bring stereopure and
allele-specific medicines to clinic

3

clinical studies initiated in 2017

5

nucleic acid modalities being advanced with Wave stereopure chemistry

12+

discovery programs

 

Investor Relations

Recent News

May 22, 2019

Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass. , May 22, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

Recent News

May 22, 2019

Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass. , May 22, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive
Recent News and Events

Copyright West LLC. Minimum 15 minutes delayed.